ImmunoGen Story

<div class='circular--portrait' style='background:#800000;color: #F8F8FF;font-size:4em;'>IM</div>
IMGN -- USA Stock  

USD 3.86  0.36  10.29%

While some of us are excited about healthcare space, it makes sense to outline ImmunoGen in greater detail to make a better perception of its potential. As expected, ImmunoGen is starting to reaffirm its true potential as institutional investors are becoming more and more confident in the future outlook. The company returns are very sensitive to each other to returns on the market. As market twists, the company is expected to follow. Conflicting basic indicators of the company may also entail signs of long-standing losses for ImmunoGen institutional investors. ImmunoGen is scheduled to announce its earnings today. The next earnings report is expected on the 6th of November 2020.
Published over a month ago
View all stories for ImmunoGen | View All Stories
Will ImmunoGen (NASDAQ:IMGN) price continue to thrive in August?
This firm's average rating is Buy from 6 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on ImmunoGen market sentiment investors' perception of the future value of ImmunoGen. Let us look at a few aspects of ImmunoGen technical analysis.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of ImmunoGen. In general, we focus on analyzing ImmunoGen stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build ImmunoGen's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of ImmunoGen's intrinsic value. In addition to deriving basic predictive indicators for ImmunoGen, we also check how macroeconomic factors affect ImmunoGen price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.

How does ImmunoGen Stands against Peers?

Analyzing ImmunoGen competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to ImmunoGen across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out ImmunoGen Competition Details

How ImmunoGen utilizes its cash?

To perform a cash flow analysis of ImmunoGen, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash ImmunoGen is receiving and how much cash it distributes out in a given period. The ImmunoGen cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. ImmunoGen Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (95.34 Million)

Acquisition by Altschuller Susan of 300000 shares of ImmunoGen subject to Rule 16b-3

Legal trades by ImmunoGen insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
ImmunoGen insider trading alert for grant of common stock (right to buy) by Altschuller Susan, SVP and CFO, on 22nd of July 2020. This event was filed by Immunogen Inc with SEC on 2020-07-22. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Closer look at ImmunoGen Standard Deviation

ImmunoGen has current Standard Deviation of 5.16. The Standard Deviation is a measure of how spread out the prices or returns of an asset are on average. It is the most widely used risk indicator in the field of investing and finance. Standard Deviation is commonly used to measure confidence in statistical conclusions regarding certain equity instruments or portfolios of equities.

Standard deviation is applied to the annual rate of return of an investment to measure the investment's volatility. Standard deviation is also known as historical volatility and is used by investors as a gauge for the amount of expected market volatility. A large standard deviation usually indicates that the data points are far from the mean and a small standard deviation indicates that they are clustered closely around the mean.

Standard Deviation 
=  
SQRT(V) 
 = 
5.16
SQRT = Square root notation
V =   Variance of ImmunoGen returns
Let's now compare ImmunoGen Standard Deviation to its closest peers:
IMGN
DNLI
DMPI
EQ
DYAI
IMGN5.164174963853443
DNLI3.94
DMPI9.51
EQ90.43
DYAI6.54

Our take on today ImmunoGen thrive

The expected short fall is down to -4.61 as of today. ImmunoGen exhibits above-average semi-deviation for your current time horizon. We encourage investors to investigate ImmunoGen individually to make sure intended market timing strategies and available technical indicagtors are consistent with their estimates about ImmunoGen future systematic risk.

Whereas some firms under the biotechnology industry are still a bit expensive, ImmunoGen may offer a potential longer-term growth to institutional investors. To conclude, as of the 31st of July 2020, we see that ImmunoGen almost mirrors the market. The company is undervalued with low chance of financial distress within the next 24 months. However, our primary 30 days buy-or-sell advice on the company is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of ImmunoGen. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com